MedWatch

Biogen beats Novo to the punch

Biogen and the Danish drug-giant Novo Nordisk are locked in a race to access the hemophilia market first – a market that could yield billions. According to an industry analyst, it looks as if the US biotech company has beaten the Novo to the punch with its long-acting hemophilia drug.

Foto: Novo Nordisk/PR

Biogen Idec and Novo Nordisk both have a potential blockbuster for the treatment of hemophilia A in their pipelines – a market believed to have a potential of just about 30 billion Danish kroner, or 500 million dollars.

With the recent announcement of positive results from a phase III study Biogen edges ahead of its Danish rivals in the race to put a long-acting hemophilia drug on the market first. The study showed that 98 % of bleeding incidents in the trial population could be controlled with one or two injections of Biogen’s rFVIIIFc.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier